ESC 365 - Non-clinical evaluation of YN001-a promising drug for atherosclerotic therapy by targeted delivery system

ESC Professional Premium Access

Non-clinical evaluation of YN001-a promising drug for atherosclerotic therapy by targeted delivery system

Session: Drug-related risk management in chronic coronary syndromes

Topic: Pharmacotherapy

Speaker: Doctor Q. Ma (Beijing, CN)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Qian Ma

Beijing Anzhen Hospital, Beijing (China)

0 follower

6 more presentations in this session

Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study

Speaker: Doctor J. Shanmuganathan (Aalborg, DK)

Combination of nicorandil and beta-adrenergic receptor blockers in patients with coronary heart disease: a real-world observational study

Speaker: Professor N. Zhou (Wuhan, CN)

Cardioprotective potential of exosomes derived from blood outgrowth endothelial cells in ischemic cardiomyopathy

Speaker: Doctor M. Wu (Leuven, BE)

PSRC1 rs599839 G allele may promote protection from coronary artery disease in a Madeira Island population

Speaker: Mr F. Sousa (Funchal, PT)

Effects on re-endothelialisation with Bydureon treatment add on to insulin versus insulin alone, both in combination with metformin in type 2 diabetic subjects: Rebuild study

Speaker: Doctor I. Santos-Pardo (Stockholm, SE)

Access the full session

Drug-related risk management in chronic coronary syndromes

Speakers: Doctor Q. Ma, Doctor J. Shanmuganathan, Professor N. Zhou, Doctor M. Wu, Mr F. Sousa...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources